biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > MTX110

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Dec 19, 2022 9:12pm

125 Views

Post# 35181210

RE:RE:RE: MTX110

MBT123 wrote: Isn't %10 of something better than %100 of nothing? I mean we're close either way but it's painfully obvious for "whatever" reason no pharma or anyone wanted this thing for even coffee change for them..I'll cash out at .25 next month..That maybe high but I feel like it's that or zilch

License an early stage asset to pharma and they can want it all too leaving you with a small royalty, etc. We've watched BTI struggle with the licensing model. Pharma also works on their own timeline and can demand secrecy. Midatech appears to like what it sees concerning its assets and wants to escape the early stage licensing model. They want the assets for themselves. When someone wants an asset for themselves that can be the best of all. BTI appears to like what it sees in Midatech and also wants to escape the early-stage licensing model. They want to combine proprietary assets to gain scale and become a therapeutics company in their own right that develops assets in the clinic. Licensing can support the development of therapeutics. Denali Therapeutics develops its own assets in trials. This merger is transformative.

Midatech news release:

transition from a drug delivery platform-based company to a therapeutics company;
a focus on rare and orphan diseases, conferring advantages such as smaller, lower cost studies, higher in-market prices; and market exclusivity for seven years and 10 years in the US and Europe, respectively;
a robust internal therapeutics pipeline of five programmes in six indications and therefore less reliance on R&D collaborations with third parties;
access to a number of enabling platform technologies that have been validated by partnerships and licenses with pharmaceutical companies with potential milestone payments, should various performance conditions be met, totalling in excess of US$200 million;
improved news flow including clinical data; and
lower combined overheads.